Published in Curr Pharm Des on January 01, 2014
Alzheimer's Disease: Mechanism and Approach to Cell Therapy. Int J Mol Sci (2015) 0.79
Contributions of nonhematopoietic cells and mediators to immune responses: implications for immunotoxicology. Toxicol Sci (2015) 0.75
The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol (2004) 19.38
Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 16.31
Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science (2005) 14.43
Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 13.60
Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 13.45
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
Alternative activation of macrophages: mechanism and functions. Immunity (2010) 12.43
Axonal transection in the lesions of multiple sclerosis. N Engl J Med (1998) 12.21
ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci (2005) 11.55
Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci (2007) 11.11
Immunology of multiple sclerosis. Annu Rev Immunol (2005) 9.08
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature (1996) 8.99
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 8.50
Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci (2006) 8.25
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol (1995) 8.09
Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med (1993) 8.03
Decoding the patterns of self and nonself by the innate immune system. Science (2002) 7.19
Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol (2009) 6.79
2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun (1995) 6.55
A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature (2000) 6.12
Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature (1994) 5.70
CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science (2003) 5.22
Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol (2007) 5.01
Inflammation in neurodegenerative disease--a double-edged sword. Neuron (2002) 4.95
Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature (1998) 4.86
Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J Neurosci (2009) 4.83
Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem (1995) 4.53
Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience (1990) 4.52
Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science (2000) 4.41
Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience (1998) 4.39
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
Endocannabinoid signaling in the brain. Science (2002) 4.28
Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol (2007) 4.14
Integrin-associated protein (CD47) and its ligands. Trends Cell Biol (2001) 3.79
The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron (2006) 3.55
Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci (1999) 3.45
Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat Genet (2000) 3.39
Phagocytosis: elegant complexity. Immunity (2005) 3.27
Inflammation in neurodegenerative diseases. Immunology (2010) 3.22
Microglial cell origin and phenotypes in health and disease. Nat Rev Immunol (2011) 3.20
A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J Exp Med (2001) 3.18
The morbid anatomy of the demyelinative disease. Am J Med (1952) 3.17
Heterogeneity of microglial activation in the innate immune response in the brain. J Neuroimmune Pharmacol (2009) 3.04
What is immune privilege (not)? Trends Immunol (2006) 3.02
Innate immunity: the missing link in neuroprotection and neurodegeneration? Nat Rev Neurosci (2002) 2.97
T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol (2010) 2.94
Friendly and dangerous signals: is the tissue in control? Nat Immunol (2007) 2.87
Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci (2003) 2.84
Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol (2000) 2.83
beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci (2001) 2.81
Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci U S A (1990) 2.79
Changing face of microglia. Science (2010) 2.79
Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function. Immunity (2000) 2.64
Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J Mol Med (Berl) (1997) 2.55
The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron (2006) 2.55
Microglia biology in health and disease. J Neuroimmune Pharmacol (2006) 2.53
Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J Biol Chem (2000) 2.48
CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol (2002) 2.45
TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol (2009) 2.44
Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol (2003) 2.38
A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem (2009) 2.37
The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci (2010) 2.37
The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem (2005) 2.34
Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A (1995) 2.33
Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J Neurosci (2007) 2.32
Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci (2005) 2.31
Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol (2008) 2.29
Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci U S A (1992) 2.23
Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem (1997) 2.18
Role of inflammation in neurodegenerative diseases. Curr Opin Neurol (2005) 2.12
The origin and nature of ramified and amoeboid microglia: a historical review and current concepts. Glia (1993) 2.11
Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol (2007) 2.08
mRNA up-regulation of MHC II and pivotal pro-inflammatory genes in normal brain aging. Neurobiol Aging (2006) 2.06
Inflammatory processes in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry (2003) 2.04
Heterogeneous expression of the triggering receptor expressed on myeloid cells-2 on adult murine microglia. J Neurochem (2002) 2.00
Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest (1978) 1.99
Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry (2005) 1.97
Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci (1995) 1.94
Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain (2007) 1.94
Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc Natl Acad Sci U S A (2006) 1.92
Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis. Eur J Immunol (2007) 1.88
Mutations in TREM2 lead to pure early-onset dementia without bone cysts. Hum Mutat (2008) 1.78
Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature (2000) 1.77
Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem (1997) 1.72
Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia (2010) 1.70
Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int J Dev Neurosci (2006) 1.68
Siglecs in innate immunity. Curr Opin Pharmacol (2005) 1.64
MAP kinase activation in macrophages. J Leukoc Biol (2001) 1.64
Cues for apoptotic cell engulfment: eat-me, don't eat-me and come-get-me signals. Trends Cell Biol (2003) 1.63
The role of microglia in central nervous system immunity and glioma immunology. J Clin Neurosci (2009) 1.62
Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci (2002) 1.61
Molecular mechanisms of CD200 inhibition of mast cell activation. J Immunol (2004) 1.57
Macrophage-depletion induced impairment of experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression. Neurobiol Dis (2005) 1.57
Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology (2000) 1.56
Regulation of myeloid cell function through the CD200 receptor. J Immunol (2006) 1.56
Associative short-term synaptic plasticity mediated by endocannabinoids. Neuron (2005) 1.54
Perivascular spaces and the two steps to neuroinflammation. J Neuropathol Exp Neurol (2008) 1.52
CD200 ligand receptor interaction modulates microglial activation in vivo and in vitro: a role for IL-4. J Neurosci (2007) 1.51
Myelin-laden macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis. Brain (2005) 1.51
Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. Acta Neuropathol (2001) 1.47
Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. Br J Pharmacol (2005) 1.20
Transforming growth factor-beta 1 potentiates amyloid-beta generation in astrocytes and in transgenic mice. J Biol Chem (2003) 1.17
CINC-1 is an acute-phase protein induced by focal brain injury causing leukocyte mobilization and liver injury. FASEB J (2003) 1.11
Transforming growth factor-beta and ischemic brain injury. Cell Mol Neurobiol (2003) 1.10
The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiol Dis (2008) 1.10
TGFbeta1 regulates the inflammatory response during chronic neurodegeneration. Neurobiol Dis (2006) 1.05
Th2 cytokine response in Major Depressive Disorder patients before treatment. J Neuroimmunol (2006) 1.04
Tissue plasminogen activator prevents white matter damage following stroke. J Exp Med (2011) 1.03
The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection. Biochem Pharmacol (2006) 1.00
Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier. Chem Rev (2012) 1.00
Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder. Eur Neuropsychopharmacol (2008) 1.00
Anandamide enhances IL-10 production in activated microglia by targeting CB(2) receptors: roles of ERK1/2, JNK, and NF-kappaB. Glia (2010) 0.99
Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation. Mol Cell Neurosci (2007) 0.98
Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur J Neurosci (2008) 0.98
Glutamate controls tPA recycling by astrocytes, which in turn influences glutamatergic signals. J Neurosci (2012) 0.97
Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J Neurochem (2005) 0.96
Identification of a Rice stripe necrosis virus resistance locus and yield component QTLs using Oryza sativa x O. glaberrima introgression lines. BMC Plant Biol (2010) 0.95
tPA in the injured central nervous system: different scenarios starring the same actor? Neuropharmacology (2011) 0.94
Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. FASEB J (2005) 0.93
Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiol Dis (2005) 0.92
Anandamide inhibits IL-12p40 production by acting on the promoter repressor element GA-12: possible involvement of the COX-2 metabolite prostamide E(2). Biochem J (2008) 0.91
The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells. Brain Behav Immun (2011) 0.89
Viral models of multiple sclerosis: neurodegeneration and demyelination in mice infected with Theiler's virus. Prog Neurobiol (2012) 0.89
A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells. Biochem Pharmacol (2008) 0.89
Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation. Glia (2009) 0.86
A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis. J Neuroimmune Pharmacol (2012) 0.85
Ultra-sensitive molecular MRI of cerebrovascular cell activation enables early detection of chronic central nervous system disorders. Neuroimage (2012) 0.85
Transforming growth factor-beta1-modulated cerebral gene expression. J Cereb Blood Flow Metab (2002) 0.84
Cannabinoid system and neuroinflammation: implications for multiple sclerosis. Neuroimmunomodulation (2007) 0.83
Anandamide inhibits Theiler's virus induced VCAM-1 in brain endothelial cells and reduces leukocyte transmigration in a model of blood brain barrier by activation of CB(1) receptors. J Neuroinflammation (2011) 0.83
Transforming growth factor alpha-induced expression of type 1 plasminogen activator inhibitor in astrocytes rescues neurons from excitotoxicity. FASEB J (2002) 0.83
CD200-CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation. Glia (2012) 0.82
The endocannabinoid anandamide from immunomodulation to neuroprotection. Implications for multiple sclerosis. Vitam Horm (2009) 0.81
Therapeutic potential of CB2 targeting in multiple sclerosis. Expert Opin Ther Targets (2008) 0.81
The role of cannabinoid system on immune modulation: therapeutic implications on CNS inflammation. Mini Rev Med Chem (2005) 0.81
Enhanced glutathione efflux from astrocytes in culture by low extracellular Ca2+ and curcumin. Neurochem Res (2010) 0.81
Chemical probes for the recognition of cannabinoid receptors in native systems. Angew Chem Int Ed Engl (2012) 0.81
A reversible and selective inhibitor of monoacylglycerol lipase ameliorates multiple sclerosis. Angew Chem Int Ed Engl (2014) 0.80
[Guidelines on the appropriate use of animal models for developing therapies in multiple sclerosis]. Rev Neurol (2012) 0.80
Pharmacological activation/inhibition of the cannabinoid system affects alcohol withdrawal-induced neuronal hypersensitivity to excitotoxic insults. PLoS One (2011) 0.79
Understanding microglia-neuron cross talk: relevance of the microglia-neuron cocultures. Methods Mol Biol (2013) 0.77
Cannabidiol-induced apoptosis in murine microglial cells through lipid raft. Glia (2012) 0.77
Solution structure of the WNK1 autoinhibitory domain, a WNK-specific PF2 domain. J Mol Biol (2013) 0.76
Plant science. How plants see the invisible. Science (2012) 0.75
Correction: Novel Insights into the Multiple Sclerosis Risk Gene ANKRD55. J Immunol (2016) 0.75
Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: relevance for in vitro studies with cannabinoids in motor neuron diseases. Neurosci Lett (2011) 0.75